phosphonoacetic acid has been researched along with Diarrhea in 10 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a previous trial in which methotrexate and N-phosphonacetyl-L-aspartate (PALA) were used to modulate 5-fluorouracil (5-FU), four of six patients could not tolerate treatment at the 600 mg/m2 5-FU dose level because of mucositis, diarrhea, and a decrease in performance status." | 3.68 | Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. ( Colofiore, J; Kemeny, N; Martin, D; Sawyer, R; Schneider, A; Seiter, K; Williams, L, 1993) |
| "Diarrhea was dose-limiting; 6/13 patients had grade II or worse diarrhea at 2,600 mg/m2." | 2.68 | Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. ( Brennan, J; Hageboutros, A; Hudes, GR; LaCreta, FP; McAleer, C; Newman, EM; O'Dwyer, PJ; Ozols, RF; Rogatko, A, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (60.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doyle, JA | 1 |
| Perry, HO | 1 |
| Rubin, J | 1 |
| Moertel, CG | 1 |
| Ardalan, B | 2 |
| Jamin, D | 1 |
| Jayaram, HN | 1 |
| Presant, CA | 1 |
| Kurzrock, R | 1 |
| Yap, BS | 1 |
| Plager, C | 1 |
| Papdopoulos, N | 1 |
| Benjamin, RS | 1 |
| Valdivieso, M | 1 |
| Bodey, GP | 1 |
| Creagan, ET | 1 |
| O'Connell, MJ | 1 |
| Kovach, JS | 1 |
| Gralla, RJ | 1 |
| Casper, ES | 1 |
| Natale, RB | 1 |
| Yagoda, A | 1 |
| Young, CW | 1 |
| Meropol, NJ | 1 |
| Creaven, PJ | 1 |
| Petrelli, NJ | 1 |
| Leichman, CG | 1 |
| Fleming, TR | 1 |
| Muggia, FM | 1 |
| Tangen, CM | 1 |
| Doroshow, JH | 1 |
| Meyers, FJ | 1 |
| Holcombe, RF | 1 |
| Weiss, GR | 1 |
| Mangalik, A | 1 |
| Hageboutros, A | 1 |
| Rogatko, A | 1 |
| Newman, EM | 1 |
| McAleer, C | 1 |
| Brennan, J | 1 |
| LaCreta, FP | 1 |
| Hudes, GR | 1 |
| Ozols, RF | 1 |
| O'Dwyer, PJ | 1 |
| Seiter, K | 1 |
| Kemeny, N | 1 |
| Martin, D | 1 |
| Schneider, A | 1 |
| Williams, L | 1 |
| Colofiore, J | 1 |
| Sawyer, R | 1 |
| Erlichman, C | 1 |
| Strong, JM | 1 |
| Wiernik, PH | 1 |
| McAvoy, LM | 1 |
| Cohen, MH | 1 |
| Levine, AS | 1 |
| Hubbard, SM | 1 |
| Chabner, BA | 1 |
1 review available for phosphonoacetic acid and Diarrhea
| Article | Year |
|---|---|
Metastatic colorectal cancer: advances in biochemical modulation and new drug development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neoplasms; Diar | 1995 |
2 trials available for phosphonoacetic acid and Diarrhea
| Article | Year |
|---|---|
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chem | 1995 |
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspart | 1995 |
7 other studies available for phosphonoacetic acid and Diarrhea
| Article | Year |
|---|---|
Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
Topics: Adult; Aged; Arthritis; Aspartic Acid; Diarrhea; Drug Eruptions; Female; Follow-Up Studies; Humans; | 1984 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
Phase II evaluation of PALA in patients with refractory metastatic sarcomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Bone Neoplasms; Diarrhea; Drug Evaluati | 1984 |
A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
Topics: Alanine; Aspartic Acid; Diarrhea; Digestive System Neoplasms; Drug Administration Schedule; Drug Eva | 1983 |
Phase I trial of PALA.
Topics: Antineoplastic Agents; Aspartic Acid; Brain Diseases; Diarrhea; Dose-Response Relationship, Drug; Ga | 1980 |
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Diarrhea; Drug Synergism | 1993 |
Phase I trial of N-(phosphonacetyl)-L-aspartate.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Colonic Neoplasms; Diarrhea; Drug Eruptions; Drug Evaluation | 1979 |